{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:46:12Z","timestamp":1778715972441,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T00:00:00Z","timestamp":1396569600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s11864-014-0286-4","type":"journal-article","created":{"date-parts":[[2014,4,3]],"date-time":"2014-04-03T02:32:34Z","timestamp":1396492354000},"page":"262-268","source":"Crossref","is-referenced-by-count":31,"title":["Radiotherapy of Follicular Lymphoma: Updated Role and New Rules"],"prefix":"10.1007","volume":"15","author":[{"given":"Joachim","family":"Yahalom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,4]]},"reference":[{"key":"286_CR1","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/1097-0142(19821215)50:12<2699::AID-CNCR2820501202>3.0.CO;2-A","volume":"50","author":"T Anderson","year":"1982","unstructured":"Anderson T, Chabner BA, Young RC, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer. 1982;50:2699\u2013707.","journal-title":"Cancer"},{"key":"286_CR2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/CCO.0b013e328356898b","volume":"24","author":"CA Jacobson","year":"2012","unstructured":"Jacobson CA, Freedman AS. Early stage follicular lymphoma, current management and controversies. Curr Opin Oncol. 2012;24:475\u20139.","journal-title":"Curr Opin Oncol"},{"key":"286_CR3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.semradonc.2007.02.006","volume":"17","author":"RW Tsang","year":"2007","unstructured":"Tsang RW, Gospodarowicz MK. Low-grade non-hodgkin lymphomas. Semin Radiat Oncol. 2007;17:198\u2013205.","journal-title":"Semin Radiat Oncol"},{"key":"286_CR4","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","volume":"21","author":"RL Haas","year":"2003","unstructured":"Haas RL, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21:2474\u201380.","journal-title":"J Clin Oncol"},{"key":"286_CR5","unstructured":"Zelenetz AD, et al: NCCN guidelines for non-Hodgkin lympphoma V.2013.2. 2013."},{"key":"286_CR6","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.25149","volume":"116","author":"TJ Pugh","year":"2010","unstructured":"Pugh TJ, Ballonoff A, Newman F, et al. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2010;116:3843\u201351.","journal-title":"Cancer"},{"key":"286_CR7","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","volume":"14","author":"MP Mac Manus","year":"1996","unstructured":"Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282\u201390.","journal-title":"J Clin Oncol"},{"key":"286_CR8","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","volume":"116","author":"BA Campbell","year":"2010","unstructured":"Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116:3797\u2013806.","journal-title":"Cancer"},{"key":"286_CR9","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","volume":"27","author":"JW Friedberg","year":"2009","unstructured":"Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27:1202\u20138.","journal-title":"J Clin Oncol"},{"key":"286_CR10","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454\u20139.","journal-title":"J Clin Oncol"},{"key":"286_CR11","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30:3368\u201375.","journal-title":"J Clin Oncol"},{"key":"286_CR12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1148\/108.3.675","volume":"108","author":"Z Fuks","year":"1973","unstructured":"Fuks Z, Kaplan H. Recurrence rates following radiation therapy of nodular and diffuse malignant lymphomas. Radiology. 1973;108:675\u20139.","journal-title":"Radiology"},{"key":"286_CR13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86\u201392. A practice-changing, randomized study on lowering RT dose in aggressive and indolent lymphomas.","journal-title":"Radiother Oncol"},{"key":"286_CR14","doi-asserted-by":"crossref","unstructured":"Illidge T, Specht L, Yahalom J, et al: Modern radiation therapy for nodal non Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Rad Oncol Biol Phys, 2014. The most detailed comprehensive guide for designing the RT field and choosing the dose - a consensus among international lymphoma radiation oncology experts.","DOI":"10.1016\/j.ijrobp.2014.01.006"},{"key":"286_CR15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijrobp.2012.12.024","volume":"86","author":"AL Russo","year":"2013","unstructured":"Russo AL, Chen YH, Martin NE, et al. Low-dose involved-field radiation in the treatment of non-Hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys. 2013;86:121\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"286_CR16","doi-asserted-by":"crossref","unstructured":"Hoskin PJ, Kirkwood AA, Popova B, et al: 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol, 2014. An important study on the limits of further lowering the RT dose for indolent lymphoma.","DOI":"10.1016\/S1470-2045(14)70036-1"},{"key":"286_CR17","doi-asserted-by":"crossref","unstructured":"Specht L: Radiotherapy for indolent lymphomas: how much is enough? Lancet Oncol, 2014. A well-conceived editorial on the limits and appropriateness of loweing the dose for potentially curative patients with indolent lymphoma.","DOI":"10.1016\/S1470-2045(14)70070-1"},{"key":"286_CR18","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0889-8588(05)70469-X","volume":"11","author":"MP Mac Manus","year":"1997","unstructured":"Mac Manus MP, Hoppe RT. Overview of treatment of localized low-grade lymphomas. Hematol Oncol Clin North Am. 1997;11:901\u201318.","journal-title":"Hematol Oncol Clin North Am"},{"key":"286_CR19","doi-asserted-by":"crossref","unstructured":"Specht L, Yahalom J, Illidge T, et al: Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys, 2013.","DOI":"10.1016\/j.ijrobp.2013.05.005"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-014-0286-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-014-0286-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-014-0286-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T01:17:36Z","timestamp":1565313456000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-014-0286-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1007\/s11864-014-0286-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,4]]}}}